BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 15033130)

  • 21. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
    Lecendreux M; Plazzi G; Dauvilliers Y; Rosen CL; Ruoff C; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
    J Clin Sleep Med; 2022 Sep; 18(9):2217-2227. PubMed ID: 35689598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms.
    J Toxicol Clin Toxicol; 2003; 41(2):131-5. PubMed ID: 12733850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
    Bogan RK; Foldvary-Schaefer N; Skowronski R; Chen A; Thorpy MJ
    CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy.
    Black J; Pardi D; Hornfeldt CS; Inhaber N
    J Clin Sleep Med; 2010 Dec; 6(6):596-602. PubMed ID: 21206549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
    Bogan RK; Roth T; Schwartz J; Miloslavsky M
    J Clin Sleep Med; 2015 Apr; 11(4):427-32. PubMed ID: 25580605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice.
    Drakatos P; Lykouras D; D'Ancona G; Higgins S; Gildeh N; Macavei R; Rosenzweig I; Steier J; Williams AJ; Muza R; Kent BD; Leschziner G
    Sleep Med; 2017 Jul; 35():80-84. PubMed ID: 28619187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Narcolepsy: a new perspective on diagnosis and treatment].
    Fronczek R; van der Zande WL; van Dijk JG; Overeem S; Lammers GJ
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):856-61. PubMed ID: 17472116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate.
    Murali H; Kotagal S
    Sleep; 2006 Aug; 29(8):1025-9. PubMed ID: 16944670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium oxybate and sleep apnea: a clinical case.
    Hartley S; Quera-Salva MA; Machou M
    J Clin Sleep Med; 2011 Dec; 7(6):667-8. PubMed ID: 22171208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium oxybate for excessive daytime sleepiness in narcolepsy-cataplexy.
    Arnulf I; Mignot E
    Sleep; 2004 Nov; 27(7):1242-3. PubMed ID: 15586777
    [No Abstract]   [Full Text] [Related]  

  • 31. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy.
    Weaver TE; Cuellar N
    Sleep; 2006 Sep; 29(9):1189-94. PubMed ID: 17040006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of acute administration of sodium oxybate on nocturnal sleep polysomnography and on multiple sleep latency test in narcolepsy with cataplexy.
    Plazzi G; Pizza F; Vandi S; Aricò D; Bruni O; Dauvilliers Y; Ferri R
    Sleep Med; 2014 Sep; 15(9):1046-54. PubMed ID: 25087195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients.
    Borgen LA; Okerholm RA; Lai A; Scharf MB
    J Clin Pharmacol; 2004 Mar; 44(3):253-7. PubMed ID: 14973300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium oxybate: a review of its use in the management of narcolepsy.
    Robinson DM; Keating GM
    CNS Drugs; 2007; 21(4):337-54. PubMed ID: 17381187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
    Black J; Swick T; Bogan R; Lai C; Carter LP
    Sleep Med; 2016 Aug; 24():57-62. PubMed ID: 27810187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EFNS guidelines on management of narcolepsy.
    Billiard M; Bassetti C; Dauvilliers Y; Dolenc-Groselj L; Lammers GJ; Mayer G; Pollmächer T; Reading P; Sonka K;
    Eur J Neurol; 2006 Oct; 13(10):1035-48. PubMed ID: 16987156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy.
    Scharf MB; Brown D; Woods M; Brown L; Hirschowitz J
    J Clin Psychiatry; 1985 Jun; 46(6):222-5. PubMed ID: 3888969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy.
    Roth T; Dauvilliers Y; Guinta D; Alvarez-Horine S; Dynin E; Black J
    J Sleep Res; 2017 Aug; 26(4):407-414. PubMed ID: 27807903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium oxybate (GHB) for treatment of cataplexy.
    Borgen LA; Cook HN; Hornfeldt CS; Fuller DE
    Pharmacotherapy; 2002 Jun; 22(6):798-9; discussion 799. PubMed ID: 12066974
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.